安慰剂效应——Ted Kaptchuk找到了“假”药中的真成分

2013-05-20 MedSci MedSci原创

安慰剂效应的发现者Ted Kaptchuk     在接受Ted Kaptchuk的首次随机临床药物测试两周之后、270名被测对象中大约有三分之一向他抱怨严重的副作用。所有患者参与这项研究都是为了缓解他们严重的臂痛。腕隧道症、肌腱炎。肘部、肩膀、手腕部位的长期疼痛。这项研究有一部分是让一半被测者服用止痛片、而其余的接受针灸治疗。但这两群人都开始诉说他们起不了床。

安慰剂效应的发现者Ted Kaptchuk     在接受Ted Kaptchuk的首次随机临床药物测试两周之后、270名被测对象中大约有三分之一向他抱怨严重的副作用。所有患者参与这项研究都是为了缓解他们严重的臂痛。腕隧道症、肌腱炎。肘部、肩膀、手腕部位的长期疼痛。这项研究有一部分是让一半被测者服用止痛片、而其余的接受针灸治疗。但这两群人都开始诉说他们起不了床。药片令他们变得反应迟缓、而针灸又导致红肿。一些患者疼痛到无法忍受的地步。“副作用太厉害了”Kaptchuk解释道 。不可思议的是、症状表现得和这些患者在治疗之前被警告可能产生的副作用完全一致。更加令人震惊的是、其余大部分患者报告疼痛的确缓解、而且接受针灸治疗的效果比那些服用止痛片的更加明显。这可是非同寻常的发现:以前从未有人证明过针灸比止痛片更有效。但其实Kaptchuk的研究也没有证明这一点。因为他的团队提供给患者们的药片实际上是用玉米淀粉糊做的。而所谓“针灸”是一个骗局、用的是可缩回的针、从未真正刺穿过皮肤。这项研究目的不在于比较两种治疗方案的效果、而是为了比较两种骗局。   

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702911, encodeId=5f0d1e02911ed, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Tue Jan 28 08:25:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993446, encodeId=8bb11993446d3, content=<a href='/topic/show?id=24fa14828b6' target=_blank style='color:#2F92EE;'>#PTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14828, encryptionId=24fa14828b6, topicName=PTC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/TnzXXl41yf6V8fHrDb5JdtxOgpaY6vplUhHtL8BzDh1xMtcap9H1IOlE8umxPGovhIuVkeGTY26eNUFCFaOheQ/132, createdBy=29702500197, createdName=ms6279672939590805, createdTime=Sun Aug 11 04:25:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304309, encodeId=b5a2130430948, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
    2014-01-28 aliceclz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1702911, encodeId=5f0d1e02911ed, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Tue Jan 28 08:25:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993446, encodeId=8bb11993446d3, content=<a href='/topic/show?id=24fa14828b6' target=_blank style='color:#2F92EE;'>#PTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14828, encryptionId=24fa14828b6, topicName=PTC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/TnzXXl41yf6V8fHrDb5JdtxOgpaY6vplUhHtL8BzDh1xMtcap9H1IOlE8umxPGovhIuVkeGTY26eNUFCFaOheQ/132, createdBy=29702500197, createdName=ms6279672939590805, createdTime=Sun Aug 11 04:25:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304309, encodeId=b5a2130430948, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1702911, encodeId=5f0d1e02911ed, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Tue Jan 28 08:25:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993446, encodeId=8bb11993446d3, content=<a href='/topic/show?id=24fa14828b6' target=_blank style='color:#2F92EE;'>#PTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14828, encryptionId=24fa14828b6, topicName=PTC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/TnzXXl41yf6V8fHrDb5JdtxOgpaY6vplUhHtL8BzDh1xMtcap9H1IOlE8umxPGovhIuVkeGTY26eNUFCFaOheQ/132, createdBy=29702500197, createdName=ms6279672939590805, createdTime=Sun Aug 11 04:25:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304309, encodeId=b5a2130430948, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]